Does Cigna Cover Mounjaro? Express Scripts and the T2D Approval Path

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited · Author: FormBlends Editorial

Key Takeaways

• Cigna covers Mounjaro for T2D at Tier 3 with PA through Express Scripts
• Coverage is more reliable than for Zepbound because T2D treatment isn't subject to AOM carve-outs
• Standard PA requires T2D diagnosis, recent A1C, and metformin trial documentation
• Step therapy through additional T2D agents is common; exceptions are available within 72 hours
• The Lilly Mounjaro savings card caps eligible commercial copays at $25

Direct answer

Yes, Cigna covers Mounjaro for type 2 diabetes on its standard commercial formulary at Tier 3 with prior authorization administered through Express Scripts. As of May 2026, confirm with your specific plan. Coverage is more consistent than for Zepbound because Mounjaro's T2D label exempts it from AOM exclusions affecting Zepbound on many employer plans. Standard PA criteria include T2D diagnosis documentation (ICD-10 E11 series), recent A1C ≥ 7.0%, completed metformin trial, and (on most plans) trial of additional oral T2D agents. Step-therapy exceptions are available under federal law within 72 hours when prior treatment failure or contraindication is documented.

Table of contents

1. How Cigna and Express Scripts process Mounjaro PAs
2. Standard PA criteria via Express Scripts
3. Cigna step therapy for Mounjaro
4. Why Mounjaro coverage is more uniform than Zepbound
5. Common denial reasons
6. Effective appeal strategy
7. Cost scenarios across plan types
8. Cigna Medicare Advantage
9. The Mounjaro savings card mechanics
10. FAQ
11. Sources

How Cigna and Express Scripts process Mounjaro PAs

Express Scripts is Cigna's pharmacy benefit manager and a sister company under the Cigna Group corporate umbrella since the 2018 acquisition. Mounjaro prior authorizations submitted through Cigna are routed to Express Scripts clinical review, which applies the published criteria and returns the approval or denial.

Operationally:

• PAs submit through provider portals (CoverMyMeds, Surescripts) into the Express Scripts queue
• Standard PA review: 24-72 hours
• Expedited (urgent) review: within 24 hours
• Denial letters arrive on Express Scripts letterhead
• Appeals address to Express Scripts Clinical Review, not the Cigna medical director's office

Standard PA criteria via Express Scripts

Cigna's published Mounjaro PA criteria (current May 2026):

• Documented type 2 diabetes diagnosis (ICD-10 E11.0 through E11.9)
• Recent A1C measurement (within 90 days), generally ≥ 7.0% on current therapy
• Age ≥ 18
• Trial of metformin at maximum tolerated dose for ≥ 3 months (unless contraindicated)
• Most plans: trial of one additional oral T2D agent
• Some plans: trial of one GLP-1 (Ozempic or Trulicity) before Mounjaro
• Prescriber attestation of continued diet/exercise counseling
• No concurrent GLP-1 use
• Reauthorization at 6 months: A1C improvement documented

Cigna step therapy for Mounjaro

Step	Required treatment	Duration
1	Metformin (unless contraindicated)	3 months at maximum tolerated dose
2	One additional oral T2D agent (DPP-4, SGLT2, sulfonylurea)	3 months
3 (some plans)	Ozempic or Trulicity	3 months at therapeutic dose
4	Mounjaro approved	-

Step-therapy exceptions are required by federal law to receive response within 72 hours. The most successful exceptions cite prior GLP-1 trials elsewhere, metformin intolerance with documented side effects, or rapid A1C deterioration requiring more potent agent.

Why Mounjaro coverage is more uniform than Zepbound

Cigna's Zepbound coverage varies because of employer AOM carve-outs. Mounjaro coverage doesn't vary that way because T2D treatment is a covered medical category in every commercial plan.

• Mounjaro (T2D): Covered across essentially all Cigna commercial plans
• Zepbound (weight loss): Covered only on plans with AOM benefits
• Zepbound (OSA after December 2024): Coverage expanding as plans update OSA criteria

For T2D patients with Cigna, the path to Mounjaro is generally clear. The variables are PA documentation completeness and step-therapy compliance.

Common denial reasons

Express Scripts denial codes you might see for Mounjaro:

• T2D diagnosis not documented in claims history
• A1C measurement outdated (more than 90 days)
• A1C shows controlled diabetes (under 7.0%) without documented progression
• Metformin trial not documented at maximum tolerated dose
• Step therapy through additional oral T2D agent not completed
• Concurrent GLP-1 on the patient's claim record
• Quantity limit issue (prescription quantity outside standard)

Effective appeal strategy

Strong Cigna/Express Scripts appeals for Mounjaro denials include:

1. A1C trend documentation: 3+ measurements over 6-12 months showing inadequate control
2. Specific metformin trial: dates, doses, side effects, and outcome
3. Prior treatment documentation for any required step drugs
4. ICD-10 codes for T2D and any complications (E11.9 uncontrolled, E11.65 with hyperglycemia, E11.22 with kidney disease, E11.21 with nephropathy)
5. Clinical trial citation: SURPASS-2 (Frias et al. 2021, NEJM) showed tirzepatide superior to semaglutide for A1C reduction in T2D
6. ADA 2026 Standards of Care reference for GLP-1/GIP-GLP-1 RA preference in T2D with obesity
7. Prescriber letter of medical necessity in clinical prose

Cost scenarios across plan types

Scenario	Monthly cost
Cigna commercial Tier 3 fixed copay	$40-$80
Cigna commercial Tier 3 with Mounjaro savings card	$25
Cigna HDHP before deductible	~$1,069 retail
Cigna Medicare Advantage Tier 3	$47-$100
Cigna Medicare after 2026 $2,000 cap	$0
Cash pay without insurance	~$1,069

Cigna Medicare Advantage

Cigna Healthspring and other Cigna Medicare Advantage prescription drug plans cover Mounjaro for T2D under Part D rules:

• Tier 3 placement typical
• PA and step therapy apply
• 2026 $2,000 OOP cap caps annual beneficiary cost
• Medicare Prescription Payment Plan available for cost smoothing
• Mounjaro Savings Card cannot be used with Medicare

The Mounjaro savings card mechanics

The Lilly Mounjaro Savings Card provides cost reduction for commercially-insured patients:

• Caps eligible patients' monthly copay at $25
• Requires active commercial insurance (the card supplements coverage, not bypasses it)
• Cannot be used with Medicare, Medicaid, Tricare, or other federal programs
• Annual max savings: $1,800 (varies by program year)
• Must enroll through the Mounjaro patient portal or pharmacy at point of fill

The card stacks with Cigna coverage when both apply. The patient pays whichever is lower between the plan copay and the card's $25 cap.

Contrary view: when Cigna's step therapy is rational

Step therapy for Mounjaro draws fewer complaints than step therapy for Zepbound because the metformin requirement aligns with ADA guidelines and decades of clinical evidence.

The defensible elements:

• Metformin is first-line per ADA, has very low cost, and has cardiovascular benefits beyond glycemic control
• Many T2D patients respond adequately to metformin alone or with one additional oral agent
• Tirzepatide is a higher-acuity therapy with more side effects than metformin

The debatable element is the prior GLP-1 step on some Cigna plans. Requiring Ozempic or Trulicity trial before Mounjaro often reflects cost negotiations rather than clinical optimization. For patients with significant A1C elevation, this delay is meaningful.

The exception process exists for these cases. Patients with documented urgency or prior GLP-1 trial typically clear exceptions.

Decision framework

If you have T2D and Cigna: Submit PA with complete documentation. A1C, metformin records, ICD-10 codes, prescriber narrative.

If denied for step therapy: File exception with prior treatment documentation. Federal 72-hour response.

If you have Cigna Medicare: Coverage applies under Part D. OOP capped at $2,000.

If you have HDHP: Plan for full retail cost during the deductible phase. The Mounjaro savings card reduces this.

If you don't have T2D: Mounjaro is not the right path. Look at Zepbound under Cigna's AOM rules.

What to verify before using this answer

The useful next step for Does Cigna Cover Mounjaro? Express Scripts and the T2D Approval Path is to verify the details that can change the decision: current labeling, insurance rules, pharmacy instructions, dose timing, contraindications, and whether the evidence applies to your diagnosis rather than only to weight loss headlines.

For this coverage and access page, the most relevant search terms are does, cigna, cover, mounjaro. Those terms point to a practical decision, so the answer should be checked against a current prescription label, payer policy, trial result, or clinician recommendation before you act.

FormBlends keeps this page focused on patient-level decision points: what is known, what is uncertain, what should be handled by a licensed clinician, and what should be avoided because it creates dosing, safety, or access risk.

FAQ

Does Cigna cover Mounjaro? Yes for T2D at Tier 3 with PA through Express Scripts.

What does Mounjaro cost with Cigna? $40-$80 Tier 3 copay typically; $25 with the savings card.

What does PA require? T2D diagnosis, A1C ≥ 7.0%, metformin trial, and (often) additional oral agent.

Why was my PA denied? Usually documentation: missing A1C, metformin trial not at max dose, or step therapy not complete.

Can I skip step therapy? Yes, with a documented exception. 72-hour federal response.

Does Cigna Medicare cover Mounjaro? Yes, under Part D rules.

How do I appeal? Submit within 180 days. Include A1C trend, metformin records, and SURPASS-2 citation.

Does Cigna cover compounded tirzepatide? No. Not FDA-approved.

Sources

1. FDA. Mounjaro (tirzepatide) prescribing information. Updated 2024.
2. Frias JP et al. Tirzepatide versus Semaglutide in T2D (SURPASS-2). NEJM. 2021.
3. Rosenstock J et al. Tirzepatide monotherapy in T2D (SURPASS-1). The Lancet. 2021.
4. American Diabetes Association. Standards of Care in Diabetes 2026.
5. Cigna Pharmacy Drug List. Standard commercial formulary. 2026 edition.
6. Express Scripts. Clinical formulary management policy. 2026.
7. CMS. Medicare Part D rules. Updated 2025.
8. Eli Lilly. Mounjaro Savings Card terms. Accessed May 2026.
9. NCQA. Step-therapy protocol exception standards. 2024.
10. Endocrine Society. T2D pharmacotherapy guidelines. 2023.
11. American Association of Clinical Endocrinologists. Comprehensive T2D management algorithm. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends provides educational information about insurance coverage policies and connects patients with independent licensed providers. We are not an insurance company, PBM, or claims administrator. Coverage decisions belong to Cigna and Express Scripts.

Compounded Medication Notice. Compounded tirzepatide is prepared by state-licensed 503A pharmacies under valid individual prescriptions. It is not FDA-approved and is not therapeutically interchangeable with Mounjaro. Cigna and Express Scripts do not cover compounded medications.

Results Disclaimer. Coverage examples, copay ranges, and PA outcomes here are typical scenarios from publicly available Cigna and Express Scripts documentation. Your specific plan benefits, employer carve-outs, and clinical situation will produce different actual outcomes.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Cigna and Express Scripts are registered trademarks of The Cigna Group. Ozempic is a registered trademark of Novo Nordisk; Trulicity is a registered trademark of Eli Lilly. FormBlends is independent and not affiliated with Cigna, Express Scripts, or Eli Lilly.